[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643032":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":30,"locations":30,"responsibleParty":31,"collaborators":30,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":30,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":30,"enrollmentInfo":42,"targetDuration":30,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":54,"whyStopped":30,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":30},{"fullName":5,"class":6},"PharmaResearch Co.,Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Conjuran","EXPERIMENTAL","Once a week for 5 injections",[13],"Device: Conjuran",{"label":15,"type":16,"description":11,"interventionNames":17},"Hyruan","ACTIVE_COMPARATOR",[18],"Drug: Hyruan",[20,25],{"type":21,"name":9,"description":11,"armGroupLabels":22,"otherNames":23},"DEVICE",[9],[24],"Polynucleotide sodium (PN)",{"type":26,"name":15,"description":11,"armGroupLabels":27,"otherNames":28},"DRUG",[15],[29],"Sodium Hyaluronate",null,{"type":32,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100643032","clinical-trial-to-evaluate-the-efficacy-and-safety-of-conjuran-after-first-and-second-cycle-repeat-administration-in-patients-with-knee-osteoarthritis-100643032",false,"NCT07646483","Clinical Trial to Evaluate the Efficacy and Safety of Conjuran® After First and Second Cycle (Repeat) Administration in Patients With Knee Osteoarthritis","A Multicenter, Randomized, Double-Blind, Active-Controlled, Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of Intra-Articular Conjuran® After First and Second Cycle (Repeat) Administration in Patients With Knee Osteoarthritis","Inclusion Criteria:\n\n* Age ≥40 years\n* Knee osteoarthritis diagnosed according to ACR criteria\n* KL grade I-III\n* Weight-bearing pain VAS ≥40 mm\n* Written informed consent\n\nExclusion Criteria:\n\n* Inflammatory or secondary arthritis\n* Recent treatment in the target knee\n* Significant uncontrolled medical conditions\n* Hypersensitivity to study device components\n* Pregnancy or breastfeeding\n* Participation in another clinical trial","ALL","40 Years",{"count":43,"type":44},180,"ESTIMATED","INTERVENTIONAL",[47],"NA","This clinical trial aims to evaluate and compare the efficacy and safety of Conjuran® and Hyruan in patients with knee osteoarthritis following first and second cycle (repeat) administration.",[50],"Knee Osteoarthritis",[52,53],"Polynucleotide sodium","Osteoarthritis","NOT_YET_RECRUITING","2026-06-10",{"date":57,"type":58},"2026-06-12","ACTUAL",{"date":60,"type":44},"2026-06",{"date":62,"type":44},"2028-07",{"name":5,"class":6}]